Abstract
Despite the fact that neurons are rarely infected by the human immunodeficiency virus (HIV), neuronal loss is common in patients with HIV infection, likely due to the effects of viral proteins and inflammatory mediators on these cells. Despite the widespread use of highly active antiretroviral therapy (HAART), at least in developed nations, cognitive impairment and other neurological complications of HIV infection persist with devastating personal and socioeconomic consequences. Fortunately, we have made important advances in recent years in defining the molecular mechanisms by which HIV infection targets the nervous system for damage. Such understanding has opened numerous therapeutic options, which are only now beginning to be exploited. This review will highlight the current state of thought regarding the neuropathogenesis of HIV infection. It will summarize the most recent research looking at the roles of both viral and host factors in mediating HIV-induced neurological disease. Utilizing this knowledge base, a framework will be outlined for current and future therapeutic trials to prevent or improve neurological complications of HIV infection.
Keywords: HIV dementia, Tat, gp120, MMP, TNF, cytokines, blood brain barrier, HAART
Current Pharmaceutical Design
Title: Developments in HIV Neuropathogenesis
Volume: 12 Issue: 9
Author(s): Avindra Nath and Jeffrey A. Rumbaugh
Affiliation:
Keywords: HIV dementia, Tat, gp120, MMP, TNF, cytokines, blood brain barrier, HAART
Abstract: Despite the fact that neurons are rarely infected by the human immunodeficiency virus (HIV), neuronal loss is common in patients with HIV infection, likely due to the effects of viral proteins and inflammatory mediators on these cells. Despite the widespread use of highly active antiretroviral therapy (HAART), at least in developed nations, cognitive impairment and other neurological complications of HIV infection persist with devastating personal and socioeconomic consequences. Fortunately, we have made important advances in recent years in defining the molecular mechanisms by which HIV infection targets the nervous system for damage. Such understanding has opened numerous therapeutic options, which are only now beginning to be exploited. This review will highlight the current state of thought regarding the neuropathogenesis of HIV infection. It will summarize the most recent research looking at the roles of both viral and host factors in mediating HIV-induced neurological disease. Utilizing this knowledge base, a framework will be outlined for current and future therapeutic trials to prevent or improve neurological complications of HIV infection.
Export Options
About this article
Cite this article as:
Nath Avindra and Rumbaugh A. Jeffrey, Developments in HIV Neuropathogenesis, Current Pharmaceutical Design 2006; 12 (9) . https://dx.doi.org/10.2174/138161206776055877
DOI https://dx.doi.org/10.2174/138161206776055877 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Immunotherapy in a Natural Model of Aβ Pathogenesis: The Aging Beagle
CNS & Neurological Disorders - Drug Targets Therapy of XDR TB with Thioridazine a Drug Beyond Patent Protection but Eligible for Patent “As New Use”
Recent Patents on Anti-Infective Drug Discovery One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine Pharmacological Modulation of Microparticle Release: New Strategies for the Management of Atherothrombotic Vascular Disorders
Current Pharmaceutical Design Relevance of Nutritional Antioxidants in Metabolic Syndrome, Ageing and Cancer: Potential for Therapeutic Targeting
Infectious Disorders - Drug Targets Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications
Current Medicinal Chemistry Statins for Diabetic Cardiovascular Complications
Current Vascular Pharmacology Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews Editorial (Hot Topic: Epidemiology & Risk Factors for Alzheimer’s Disease)
Current Alzheimer Research Pomegranate Extract Modulates Processing of Amyloid-β Precursor Protein in an Aged Alzheimer`s Disease Animal Model
Current Alzheimer Research Immunological Mechanisms of Neuropsychiatric Lupus
Current Immunology Reviews (Discontinued) Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Plants Indicated by Brazilian Indians for Disturbances of the Central Nervous System: A Bibliographical Survey
Central Nervous System Agents in Medicinal Chemistry Synthesis of Functionalized Chromenes from Meldrum’s Acid, 4- Hydroxycoumarin, and Ketones or Aldehydes
Combinatorial Chemistry & High Throughput Screening The Prevalence of Depression in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Current Alzheimer Research Can Diet and Physical Activity Limit Alzheimer's Disease Risk?
Current Alzheimer Research Conference Report: 183rd American Association for the Advancement of Science Annual Meeting, Boston MA, USA Feb 16-20, 2017: "Serving Society through Science Policy"
CNS & Neurological Disorders - Drug Targets